Novo Nordisk releases data on ElLipsE, Phase III clinical study of Victoza (liraglutide, liraglutide)

recently, diabetes giant Novo Nordisk released data from elLipsE, a phase III clinical study of VictozaThe study, the first Phase III study to be completed in the past 10 years in a group of children and adolescents with type 2 diabetes (10-17 years), assessed the efficacy and safety of Victoza (1.8 mg dose) relative to placebo, and the data confirmed the advantages of Victoza in lowering blood sugar compared to placeboCurrently, Victoza is suitable for complementary diet and exercise to improve blood sugar control in adult patients with type 2 diabetesThe ELLipsE study aims to evaluate the clinical application of Victoza in children and adolescentsVictoza (Liraglutide)Victoza (Liraglutide) is a heavy-duty glycosinotropic sinopia, and its activedrug(http://ingredient liraglutide (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonisor that stimulates the secretion of insulin naturallyin clinical studies, liraglutide not only significantly improves blood sugar control, but also effectively loses weight and improves obesity-related comorbiditiesAccording to the findings, Novo nord has developed liraglutide into a weight-loss needle, Saxenda (liraglutide, 3 mg)To date, Victoza has been approved in more than 100 countries worldwide to treat more than 1.2 million people with type 2 diabetesThe ELLipsE study included a 26-week double-blind treatment period followed by a 26-week open label extension periodThe results showed that when added to metformin (combination or non-co-use of basic insulin therapy), Victoza significantly reduced A1c at 26 weeks (primary endpoint) and 52 weeks (secondary endpoint) compared to placebo, with -0.64% and -0.50%, respectively, and placebo increased A1c at 26 weeks and 52 weeks, with an increase of 0.42% and 0.80%, respectivelyon the other hand, the Proportion of patients who reached A1c 7% at Week 26 (secondary endpoint) had significantly different data in the Vitoza treatment group (63.7%) significantly higher than in the placebo treatment group (36.5%)(p 0.001)Overall, Victoza is similar in children and adolescents with type 2 diabetes to adult sons and adolescentsIn the study, the proportion of patients reporting adverse events (AE) was similar in two groups (84.8 percent in the Victoza group and 80.9 percent in the placebo group)The incidence of adverse gastrointestinal reactions was higher in the Victoza group (33.3%) than in the placebo group (13.2%)Adverse events in the Victoza group with a incidence of up to 5% included headache, nasopharyngitis, dizziness, gastroenteritis, upper respiratory tract infections, rashes, fever and decreased appetiteOf the patients treated with Victoza, 24.2% had mild hypoglycemia and 10.3% in the placebo groupPatients treated with Victoza did not have severe hypoglycemia symptoms